These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 24446062)

  • 1. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.
    Kario K; Sun N; Chiang FT; Supasyndh O; Baek SH; Inubushi-Molessa A; Zhang Y; Gotou H; Lefkowitz M; Zhang J
    Hypertension; 2014 Apr; 63(4):698-705. PubMed ID: 24446062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (≥65 Years) With Systolic Hypertension.
    Supasyndh O; Wang J; Hafeez K; Zhang Y; Zhang J; Rakugi H
    Am J Hypertens; 2017 Nov; 30(12):1163-1169. PubMed ID: 28992296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy.
    Wang JG; Yukisada K; Sibulo A; Hafeez K; Jia Y; Zhang J
    J Hypertens; 2017 Apr; 35(4):877-885. PubMed ID: 28030431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study.
    Huo Y; Li W; Webb R; Zhao L; Wang Q; Guo W
    J Clin Hypertens (Greenwich); 2019 Jan; 21(1):67-76. PubMed ID: 30536595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.
    Ito S; Satoh M; Tamaki Y; Gotou H; Charney A; Okino N; Akahori M; Zhang J
    Hypertens Res; 2015 Apr; 38(4):269-75. PubMed ID: 25693859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.
    Ruilope LM; Dukat A; Böhm M; Lacourcière Y; Gong J; Lefkowitz MP
    Lancet; 2010 Apr; 375(9722):1255-66. PubMed ID: 20236700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effects of LCZ696 in Patients With Hypertension Compared With Angiotensin Receptor Blockers: A Meta-Analysis of Randomized Controlled Trials.
    Zhao Y; Yu H; Zhao X; Ma R; Li N; Yu J
    J Cardiovasc Pharmacol Ther; 2017 Sep; 22(5):447-457. PubMed ID: 28793821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LCZ696, a First-in-Class Angiotensin Receptor-Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension.
    Kario K; Tamaki Y; Okino N; Gotou H; Zhu M; Zhang J
    J Clin Hypertens (Greenwich); 2016 Apr; 18(4):308-14. PubMed ID: 26402918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Sacubitril/Valsartan in Chronic Type B Aortic Dissection Combined With Mild Hypertension.
    Wang X; Song F; Jiang L; Huang Z; Luo S; Li X; He X
    Am J Hypertens; 2024 Jul; 37(8):612-620. PubMed ID: 38564196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
    Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W
    J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of LCZ696 for Short-term Management of Essential Hypertension Compared With ARBs: A Meta-analysis of Randomized Controlled Trials.
    Yang S; Zhang H; Yang P; Wang C; Wu Q
    J Cardiovasc Pharmacol; 2021 May; 77(5):650-659. PubMed ID: 33951700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Crystalline Valsartan/Sacubitril (LCZ696) Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension: The RATIO Study.
    Izzo JL; Zappe DH; Jia Y; Hafeez K; Zhang J
    J Cardiovasc Pharmacol; 2017 Jun; 69(6):374-381. PubMed ID: 28338503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension.
    Supasyndh O; Sun N; Kario K; Hafeez K; Zhang J
    Hypertens Res; 2017 May; 40(5):472-476. PubMed ID: 27853163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone.
    Kusaka H; Sueta D; Koibuchi N; Hasegawa Y; Nakagawa T; Lin B; Ogawa H; Kim-Mitsuyama S
    Am J Hypertens; 2015 Dec; 28(12):1409-17. PubMed ID: 25762811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
    Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
    Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study.
    Williams B; Cockcroft JR; Kario K; Zappe DH; Cardenas P; Hester A; Brunel P; Zhang J
    BMJ Open; 2014 Feb; 4(2):e004254. PubMed ID: 24496699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of LCZ696 (Sacubitril/Valsartan) on Blood Pressure in Patients with Hypertension: A Meta-Analysis of Randomized Controlled Trials.
    Geng Q; Yan R; Wang Z; Hou F
    Cardiology; 2020; 145(9):589-598. PubMed ID: 32726791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
    Solomon SD; Zile M; Pieske B; Voors A; Shah A; Kraigher-Krainer E; Shi V; Bransford T; Takeuchi M; Gong J; Lefkowitz M; Packer M; McMurray JJ;
    Lancet; 2012 Oct; 380(9851):1387-95. PubMed ID: 22932717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial.
    Desai AS; Solomon S; Claggett B; McMurray JJ; Rouleau J; Swedberg K; Zile M; Lefkowitz M; Shi V; Packer M
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27296397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety Comparative of Sacubitril/Valsartan vs. Olmesartan in the Treatment of hypertension: A Meta-analysis of RCTs.
    Han Y; Zhou Y; Na J; Li F; Sun Y
    Am J Hypertens; 2023 Nov; 36(12):643-650. PubMed ID: 37596996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.